The study team found that rucaparib worked best for people with a BRCA gene change in the ovarian cancer cells. And for people with normal BRCA gene who had a higher level of DNA change in the ovarian cancer cells.
This study was open for people to join between 2013 and 2014. Researchers published the results in 2017.
About this study
204 patients were treated with rucaparib in this phase 2 study
. 28 were still having treatment when the researchers analysed the results.
Researchers tested samples of tumour and blood to find out if they had genes changes (mutations). They looked at:
- the BRCA gene change
- levels of DNA change in the cancer cells
The researchers had the results for 192 people, and:
- 40 people had a BRCA gene change
- 152 people had a normal BRCA gene
The researchers then looked at the 152 samples to find out if they had a specific type of DNA change.
- 82 had higher levels of DNA change (genomic scarring) (this is called LOH high)
- 70 had a lower levels of DNA change (this is called LOH low)
People had treatment for an average of just under 6 months. The researchers looked at how long before the cancer got worse in each of these groups.
- just under 13 months in people with a BRCA gene change
- 5.7 months in people who had higher levels of DNA change (LOH high)
- 5.2 months in people who had lower levels of DNA change (LOH low)
At 12 months they looked at whose cancer hadn’t started to grow again. This was:
- 5 out of 10 women (50%) with a BRCA gene change
- just under 3 out of 10 women (28%) with higher levels of DNA change (LOH high)
- 1 out of 10 women (10%) who had lower levels of DNA change (LOH low)
So, the study team say that rucaparib worked best for people who had the BRCA gene change. And a bit better for people who had a higher level of DNA changes compared with those who had a lesser degree of change.
Treatment worked best in people who had 1 to 2 previous treatments with platinum chemotherapy compared with those who had 3 or 4. And if the chemotherapy had worked well.
Rucaparib did cause some side effects, but they were mostly mild or moderate. The most common side effects were:
- feeling or being sick
- tiredness (fatigue)
The study team concluded that rucaparib worked best for people who had a BRCA gene change. Or for people with a normal BRCA gene who had higher levels of DNA changes.
The researchers suggest that testing tumour samples for DNA changes is useful. It can help identify if people with a normal BRCA gene change might respond to treatment or not.
The second part of ARIEL2 is looking at rucaparib in a larger group of people. These results aren’t available yet, but we hope to add them when they are.
Where do these results come from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed
) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.